Genes and Common Diseases

*Genes and common diseases* presents an up-to-date view of the role of genetics in modern medicine, reflecting the strengths and limitations of a genetic perspective.

The current shift in emphasis from the study of rare single gene disorders to common diseases brings genetics into every aspect of modern medicine, from infectious diseases to therapeutics. However, it is unclear whether this increasingly genetic focus will prove useful in the face of major environmental influences in many common diseases.

The book takes a hard and self-critical look at what can and cannot be achieved using a genetic approach and what is known about genetic and environmental mechanisms in a variety of common diseases. It seeks to clarify the goals of human genetic research by providing state-of-the-art insights into known molecular mechanisms underlying common disease processes while at the same time providing a realistic overview of the expected genetic and psychological complexity.

**Alan Wright** is a Programme Leader at the MRC Human Genetics Unit in Edinburgh.

**Nicholas Hastie** is Director of the MRC Human Genetics Unit in Edinburgh.
Genes and Common Diseases

Alan Wright
Nicholas Hastie

Foreword by David J. Weatherall
Contents

List of Contributors v
Foreword xiii

Section 1: Introductory Principles

1 Genes and their expression 3
Dirk-Jan Kleinjan

2 Epigenetic modification of chromatin 20
Donncha Dunican, Sari Pennings and Richard Meehan

3 Population genetics and disease 44
Donald F. Conrad and Jonathan K. Pritchard

4 Mapping common disease genes 59
Naomi R. Wray and Peter M. Visscher

5 Population diversity, genomes and disease 80
Gianpiero L. Cavalleri and David B. Goldstein

6 Study design in mapping complex disease traits 92
Harry Campbell and Igor Rudan

7 Diseases of protein misfolding 113
Christopher M. Dobson

8 Aging and disease 132
Thomas T. Perls

9 The MHC paradigm: genetic variation and complex disease 142
Adrian P. Kelly and John Trowsdale
<table>
<thead>
<tr>
<th>Section 2: Common Medical Disorders</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>13 Developmental disorders</td>
<td>201</td>
</tr>
<tr>
<td>Stephen P. Robertson and Andrew O. M. Wilkie</td>
<td></td>
</tr>
<tr>
<td>14 Genes, environment and cancer</td>
<td>213</td>
</tr>
<tr>
<td>D. Timothy Bishop</td>
<td></td>
</tr>
<tr>
<td>15 The polygenic basis of breast cancer</td>
<td>224</td>
</tr>
<tr>
<td>Paul D. P. Pharoah and Bruce A. J. Ponder</td>
<td></td>
</tr>
<tr>
<td>16 TP53: A master gene in normal and tumor suppression</td>
<td>233</td>
</tr>
<tr>
<td>Pierre Hainaut</td>
<td></td>
</tr>
<tr>
<td>17 Genetics of colorectal cancer</td>
<td>245</td>
</tr>
<tr>
<td>Susan M. Farrington and Malcolm G. Dunlop</td>
<td></td>
</tr>
<tr>
<td>18 Genetics of autoimmune disease</td>
<td>268</td>
</tr>
<tr>
<td>John I. Bell and Lars Fugger</td>
<td></td>
</tr>
<tr>
<td>19 Susceptibility to infectious diseases</td>
<td>277</td>
</tr>
<tr>
<td>Andrew J. Walley and Adrian V. S. Hill</td>
<td></td>
</tr>
<tr>
<td>20 Inflammatory bowel diseases</td>
<td>302</td>
</tr>
<tr>
<td>Jean-Pierre Hugot</td>
<td></td>
</tr>
<tr>
<td>21 Genetic anemias</td>
<td>316</td>
</tr>
<tr>
<td>W. G. Wood and D. R. Higgs</td>
<td></td>
</tr>
<tr>
<td>22 Genetics of chronic disease: obesity</td>
<td>328</td>
</tr>
<tr>
<td>I. Sadaf Farooqi and Stephen O'Rahilly</td>
<td></td>
</tr>
<tr>
<td>23 Type 2 diabetes mellitus</td>
<td>344</td>
</tr>
<tr>
<td>Mark I. McCarthy</td>
<td></td>
</tr>
<tr>
<td>24 Genetics of coronary heart disease</td>
<td>359</td>
</tr>
<tr>
<td>Rossi Naoumova, Stuart A. Cook, Paul Cook and Timothy J. Altman</td>
<td></td>
</tr>
<tr>
<td>25 Genetics of hypertension</td>
<td>377</td>
</tr>
<tr>
<td>B. Keavney and M. Lathrop</td>
<td></td>
</tr>
<tr>
<td>26 Obstructive pulmonary disease</td>
<td>391</td>
</tr>
<tr>
<td>Bipen D. Patel and David A. Lomas</td>
<td></td>
</tr>
<tr>
<td>27 Skeletal disorders</td>
<td>406</td>
</tr>
<tr>
<td>Robert A. Colbert</td>
<td></td>
</tr>
<tr>
<td>28 The genetics of common skin diseases</td>
<td>427</td>
</tr>
<tr>
<td>Jonathan Rees</td>
<td></td>
</tr>
<tr>
<td>29 Molecular genetics of Alzheimer’s disease and other adult-onset dementias</td>
<td>439</td>
</tr>
<tr>
<td>P. H. St George-Hyslop</td>
<td></td>
</tr>
<tr>
<td>30 Major psychiatric disorders in adult life</td>
<td>454</td>
</tr>
<tr>
<td>Amanda Elkin, Sridevi Kalidindi, Kopol Tandon and Peter McGuffin</td>
<td></td>
</tr>
<tr>
<td>31 Speech and language disorders</td>
<td>469</td>
</tr>
<tr>
<td>Gabrielle Bamby and Anthony J. Monaco</td>
<td></td>
</tr>
<tr>
<td>32 Common forms of visual handicap</td>
<td>488</td>
</tr>
<tr>
<td>Alan Wright</td>
<td></td>
</tr>
<tr>
<td>33 Genetic and environmental influences on hearing impairment</td>
<td>505</td>
</tr>
<tr>
<td>Karen P. Steel</td>
<td></td>
</tr>
<tr>
<td>34 Pharmacogenomics: clinical applications</td>
<td>516</td>
</tr>
<tr>
<td>Gillian Smith, Mark Chamberlain and C. Roland Wolf</td>
<td></td>
</tr>
<tr>
<td>Index</td>
<td>529</td>
</tr>
</tbody>
</table>
Contributors

Adrian V. S. Hill  
Human Genetics  
University of Oxford  
Wellcome Trust Centre for  
Human Genetics  
Oxford, UK

Adrian P. Kelly  
Immunology Division  
Department of Pathology  
Cambridge, UK

A. J. McMichael  
National Centre for Epidemiology and  
Population Health  
The Australian National University  
Canberra, Australia

Alan Wright  
MRC Human Genetics Unit  
Western General Hospital  
Edinburgh, UK

Amanda Elkin  
Neurogenetics Group  
Wellcome Trust Centre for Human Genetics  
Oxford, UK
List of Contributors

Andrew J. Walley  
Complex Human Genetics  
Imperial College London  
Section of Genomic Medicine  
Hammersmith Hospital  
London, UK

Andrew O. M. Wilkie  
Weatherall Institute of Molecular Medicine  
The John Radcliffe Hospital  
Oxford University  
Oxford, UK

Anthony Monaco  
Neurogenetics Group  
Wellcome Trust Centre for Human Genetics  
Oxford, UK

B. Keavney  
Institute of Human Genetics  
University of Newcastle  
Newcastle, UK

Bipen D. Patel  
Department of Public Health and Primary Care  
Institute of Public Health  
Cambridge University  
Cambridge, UK

Bruce A. J. Ponder  
Cancer Research UK Human Cancer Genetics Group  
Department of Oncology  
Strangeways Research Laboratory  
Cambridge, UK

C. Roland Wolf  
CR-UK Molecular Pharmacology Unit  
Ninewells Hospital & Medical School  
Dundee, UK

Christopher M. Dobson  
Department of Chemistry  
University of Cambridge  
Cambridge, UK

David B. Goldstein  
Department of Biology (Galton Lab)  
University College London  
London, UK

David A. Lomas  
Respiratory Medicine Unit  
Department of Medicine  
University of Cambridge  
Cambridge Institute for Medical Research  
Cambridge, UK

Dirk-Jan Kleinjan  
MRC Human Genetics Unit  
Western General Hospital  
Edinburgh, UK

Donald F. Conrad  
Department of Human Genetics  
The University of Chicago  
Chicago IL  
USA

Donncha Dunican  
MRC Human Genetics Unit  
Medical Research Council  
Western General Hospital  
Edinburgh, UK

D. R. Higgs  
MRC Molecular Haematology Unit  
Weatherall Institute of Molecular Medicine  
University of Oxford  
John Radcliffe Hospital  
Oxford, UK
List of Contributors

D. Timothy Bishop
Cancer Research UK
  Clinical Centre
St James University Hospital
University of Leeds
Leeds, UK

Gabrielle Barnby
Neurogenetics Group
Wellcome Trust Centre for Human Genetics
Oxford, UK

Geoffrey Pradella
AHRC Research Centre for Studies in
  Intellectual Property
and Technology Law
University of Edinburgh
Edinburgh, UK

Gianpiero L. Cavalleri
Department of Biology (Galton Lab)
University College London
London, UK

Gillian Smith
CR-UK Molecular Pharmacology Unit
Ninewells Hospital & Medical School
Dundee, UK

Harry Campbell
Department of Public Health Sciences
University of Edinburgh
Edinburgh, UK

I. Sadaf Farooqi
CIMR
Wellcome Trust/MRC Building
Addenbrookes’ Hospital
Cambridge, UK

Igor Rudan
School of Public Health Andrija Stampar
University of Zagreb
Zagreb, Croatia

Jean-Pierre Hugot
Department of Paediatric Gastroenterology
INSERM
Hospital Robert Debré
Paris, France

John I. Bell
The Churchill Hospital
University of Oxford
Headington
Oxford, UK

John Trowsdale
Immunology Division
Department of Pathology
Cambridge, UK

Jonathan K. Pritchard
Department of Human Genetics
The University of Chicago
Chicago IL
USA

Jonathan Rees
Department of Dermatology
University of Edinburgh
Edinburgh, UK

Karen P. Steel
Wellcome Trust Sanger Institute
Cambridge, UK

K. B. G. Dear
National Centre for Epidemiology and
  Population Health
The Australian National University
Canberra, Australia

Kopal Tandon
Neurogenetics Group
Wellcome Trust Centre for Human Genetics
Oxford, UK
List of Contributors

Lars Fugger
The Churchill Hospital
University of Oxford
Headington
Oxford, UK

Malcolm G. Dunlop
MRC Human Genetics Unit
Western General Hospital
Edinburgh, UK

Mark Chamberlain
CR-UK Molecular Pharmacology Unit
Ninewells Hospital & Medical School
Dundee, UK

M. Lathrop
Centre National de Genotypage
France

Mark I. McCarthy
Oxford Centre for Diabetes, Endocrinology & Metabolism
Churchill Hospital Site
Headington
Oxford, UK

Naomi R. Wray
Queensland Institute of Medical Research
PO Royal Brisbane Hospital
Brisbane, Australia

Nicholas D. Hastie
MRC Human Genetics Unit
Western General Hospital
Edinburgh, UK

Paul Cook
Division of Clinical Sciences
Imperial College
London, UK

Paul D. P. Pharoah
Cancer Research UK Human Cancer Genetics Group
Department of Oncology
Strangeways Research Laboratory
Worts Causeway
Cambridge, UK

Peter H. St George-Hyslop
Department of Medicine
Division of Neurology
The Toronto Hospital
University of Toronto
Toronto, Canada

Peter McGuffin
MRC Social, Genetic and Developmental Psychiatry Centre
Institute of Psychiatry
King’s College
London, UK

Peter M. Visscher
Queensland Institute of Medical Research
PO Royal Brisbane Hospital
Brisbane, Australia

Pierre Hainaut
International Agency for Research on Cancer
Lyon, France

Renate Gertz
Generation Scotland
AHRC Research Centre for Studies in Intellectual Property and Technology Law
University of Edinburgh
Edinburgh, UK

Richard Meehan
MRC Human Genetics Unit
Western General Hospital
Edinburgh, UK
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert A. Colbert</td>
<td>William S Rowe Division of Rheumatology, Liverpool, Missouri, USA</td>
</tr>
<tr>
<td>Rossi Naoumova</td>
<td>Division of Clinical Sciences, Imperial College, London, UK</td>
</tr>
<tr>
<td>Sari Pennings</td>
<td>Molecular Physiology, University of Edinburgh, Edinburgh, UK</td>
</tr>
<tr>
<td>Shawn Harmon</td>
<td>INNOMGEN ESRC Centre for Social and Economic Genomics, University of Edinburgh, UK</td>
</tr>
<tr>
<td>Sridevi Kalidindi</td>
<td>Neurogenetics Group, Wellcome Trust Centre for Human Genetics, Oxford, UK</td>
</tr>
<tr>
<td>Stephen O’Rahilly</td>
<td>CIMR Wellcome Trust/MRC Building, Addenbrookes’ Hospital, Cambridge, UK</td>
</tr>
<tr>
<td>Stephen P. Robertson</td>
<td>Department of Paediatrics and Child Health, Dunedin School of Medicine, Dunedin, New Zealand</td>
</tr>
<tr>
<td>Stuart A. Cook</td>
<td>Division of Clinical Sciences, Imperial College, London, UK</td>
</tr>
<tr>
<td>Susan M. Farrington</td>
<td>Colon Cancer Genetics Group, Department of Surgery, University of Edinburgh, Edinburgh, UK</td>
</tr>
<tr>
<td>Thomas T. Perls</td>
<td>Boston University Medical Center, Boston MA, USA</td>
</tr>
<tr>
<td>Timothy J. Aitman</td>
<td>Division of Clinical Sciences, Imperial College, London, UK</td>
</tr>
<tr>
<td>W. G. Wood</td>
<td>MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK</td>
</tr>
</tbody>
</table>
The announcement of the partial completion of the Human Genome Project was accompanied by expansive claims about the impact that this remarkable achievement will have on medical practice in the near future. The media and even some of the scientific community suggested that, within the next 20 years, many of our major killers, at least those of the rich countries, will disappear. What remains of day-to-day clinical practice will be individualized, based on a knowledge of a patient’s particular genetic make-up, and survival beyond 100 years will be commonplace. Indeed, the hyperbole continues unabated; as I write a British newspaper announces that, based on the results of manipulating genes in small animals, future generations of humans can look forward to lifespans of 200 years.

This news comes as something of a surprise to the majority of practicing doctors. The older generation had been brought up on the belief that most diseases are environmental in origin and that those that are not, vascular disease and cancer for example, can be lumped together as “degenerative”, that is the natural consequence of increasing age. More recent generations, who know something about the interactions between the environment and vascular pathology and are aware that cancer is the result of the acquisition of mutations of oncogenes, still believe that environmental risk factors are the major cause of illness; if we run six miles before breakfast, do not smoke, imbibe only homeopathic doses of alcohol, and survive on the same diets as our
hunter-gatherer forebears, we will grow old gracefully and live to a ripe old age. Against this background it is not surprising that today’s doctors were astonished to hear that a knowledge of our genetic make-up will transform their practice almost overnight.

The rather exaggerated claims for the benefits of genomics for clinical practice stem from the notion that, since twin studies have shown that there is a variable genetic component to most common diseases, the definition of the different susceptibility genes involved will provide a great deal of information about their pathogenesis and, at the same time, offer the pharmaceutical industry many new targets for their management. An even more exciting prospect is that it may become possible to identify members of the community whose genetic make-up renders them more or less prone to noxious environmental agents, hence allowing public health measures to be focused on subgroups of populations. And if this is not enough, it is also claimed that a knowledge of the relationship between drug metabolism and genetic diversity will revolutionize clinical practice; information about every patient’s genome will be available to their family practitioners, who will then be able to adjust the dosage of their drugs in line with their genetic constitution.

Enough was known long before the completion of the Genome Project to suggest that the timescale of this rosy view of genomics and health is based more on hope than reality. For example, it was already clear that the remarkable phenotypic diversity of single gene disorders, that is those whose inheritance follows a straightforward Mendelian pattern, is based on layer upon layer of complexity, reflecting multiple modifier genes and complex interactions with the environment. Even after the fruits of the Genome Project became available, and although there were a few successes, genome-wide searches for the genes involved in modifying an individual’s susceptibility to common diseases often gave ambiguous results. Similarly, early hopes that sequence data obtained from pathogen genomes, or those of their vectors, would provide targets for drug or vaccine development have been slow to come to fruition. And while there have been a few therapeutic successes in the cancer field – the development of an agent directed at the abnormal product of an oncogene in a common form of human leukemia for example – an increasing understanding of the complexity of neoplastic transformation at the molecular level has emphasized the problems of reversing this process.

In retrospect, none of these apparent setbacks should have surprised us. After all, it seems likely that most common diseases, except monogenic disorders, reflect a complex interplay between multiple and variable environmental factors and the individual responses of patients which are fine-tuned by the action of many different genes, at least some of which may have very small phenotypic effects. Furthermore, many of the refractory illnesses, particularly those of the rich countries, occur in middle or old age and hence the ill-understood biology of aging adds yet another level of complexity to their pathogenesis. Looked at in this way, it was always unlikely that there would be any quick answers to the control of our current killers.

Because the era of molecular medicine is already perceived as a time of unfulfilled promises, in no small part because of the hype with which it was heralded, the field is being viewed with a certain amount of scepticism by both the medical world and the community at large. Hence, this book, which takes a hard-headed look at the potential of the role of genetics for the future of medical practice, arrives at a particularly opportune time. The editors have amassed an excellent team of authors, all of whom are leaders in their particular fields and, even more importantly, have worked in them long enough to be able to place their potential medical roles into genuine perspective. Furthermore, by presenting their research in the kind of language which will make their findings available to practising doctors, they have performed an invaluable service by interpreting the complexities of genomic medicine for their clinical colleagues.
The truth is that we are just at the beginning of the exploration of disease at the molecular level and no-one knows where it will lead us in our search for better ways of controlling and treating common illness, either in the developing or developed countries. In effect, the position is very similar to that during the first dawnings of microbiology in the second half of the nineteenth century. In March 1882, Robert Koch announced the discovery of the organism that causes tuberculosis. This news caused enormous excitement throughout the world; an editorial writer of the London Times newspaper assured his readers that this discovery would lead immediately to the treatment of tuberculosis, yet 62 frustrating years were to elapse before Selman Waksman’s announcement of the development of streptomycin. There is often a long period between major discoveries in the research laboratory and their application in the clinic; genomics is unlikely to be an exception.

Those who read this excellent book, and I hope that there will be many, should be left in no doubt that the genetic approach to medical research and practice offers us the genuine possibility of understanding the mechanisms that underlie many of the common diseases of the richer countries, and, at the same time, provides a completely new approach to attacking the major infectious diseases which are decimating many of the populations of the developing countries. Since we have no way of knowing the extent to which the application of our limited knowledge of the environmental causes of these diseases to their control will be successful, it is vital that we make full use of what genomics has on offer.

We are only witnessing the uncertain beginnings of what is sure to be an extremely exciting phase in the development of the medical sciences; scientists should constantly remind themselves and the general public that this is the case, an approach which is extremely well exemplified by the work of the editors and authors of this fine book. I wish them and their publisher every success in this new venture.

D. J. Weatherall
Oxford